- Open
- 0.47
- High
- 0.50
- Low
- 0.47
- Close
- 0.47
- Change
- -0.02 (-5.26%)
- Volume
- 1,899,658
| 13 Oct 2026 | 07:00:03 | Final Results & Notice of AGM |
| 10 Sept 2026 | 07:00:03 | Physiomics Awarded New Contract Wins |
| 26 Aug 2026 | 10:00:01 | Holding(s) in Company |
| 21 Aug 2026 | 16:12:18 | Holding(s) in Company |
| 14 Jul 2026 | 07:00:05 | Director/PDMR Shareholding |
| 1 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 5 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 27 Oct 2023 | Annual Report and Accounts (to 2023-06-30) |
Physiomics PLC provides consulting services to pharmaceutical companies, specializing in Modelling & Simulation and Biometrics. The company utilizes proprietary tools, including its Virtual Tumour™ platform, to support drug development by offering insights derived from complex data sets. Its business model primarily operates on a fee-for-service basis, with an emphasis on oncology but increasingly expanding into other therapeutic areas such as infectious diseases and dermatology. Physiomics serves clients globally, focusing on enhancing drug development processes through data-driven approaches and flexible service offerings.
| 13 Oct 2026 | 07:00:03 | Final Results & Notice of AGM |
| 10 Sept 2026 | 07:00:03 | Physiomics Awarded New Contract Wins |
| 26 Aug 2026 | 10:00:01 | Holding(s) in Company |
| 21 Aug 2026 | 16:12:18 | Holding(s) in Company |
| 14 Jul 2026 | 07:00:05 | Director/PDMR Shareholding |
| 1 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 5 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 27 Oct 2023 | Annual Report and Accounts (to 2023-06-30) |
Physiomics PLC provides consulting services to pharmaceutical companies, specializing in Modelling & Simulation and Biometrics. The company utilizes proprietary tools, including its Virtual Tumour™ platform, to support drug development by offering insights derived from complex data sets. Its business model primarily operates on a fee-for-service basis, with an emphasis on oncology but increasingly expanding into other therapeutic areas such as infectious diseases and dermatology. Physiomics serves clients globally, focusing on enhancing drug development processes through data-driven approaches and flexible service offerings.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £75.71bn | +0.1% | |
| £1.84bn | -0.1% | |
| £46m | +0.9% | |
| £29m | — | |
| £3m | -0.5% | |
PYCPhysiomics PLC | £2m | +0.1% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £75.71bn | +0.1% | |
| £1.84bn | -0.1% | |
| £46m | +0.9% | |
| £29m | — | |
| £3m | -0.5% | |
PYCPhysiomics PLC | £2m | +0.1% |
